便携式半固体挤出装置,用于在各种环境中生产个性化药物
Paola Carou-Senra1, Lucía Rodríguez-Pombo1, Laura Castro-Martínez1
1Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela 15782 Santiago de Compostela, Spain.
International journal of pharmaceutics
|September 24, 2025
概括
手持3D笔精确地使用半固体挤出制造个性化的素片. 这种可访问的技术使得在偏远和资源有限的环境中按需制造药物成为可能.
科学领域:
- 制药技术 制药技术 制药技术
- 药物输送系统是药物输送系统.
- 个性化医疗是个性化的医疗.
背景情况:
- 3D打印 (3DP) 推进了个性化医疗,但需要为按需药物生产提供可访问,分散的解决方案.
- 手持3D笔为远程或资源有限的设置提供了便携式,节能的替代方案.
研究的目的:
- 评估使用半固体挤出 (SSE) 的手持3D笔用于制造个性化素片的首次应用.
- 为了评估通过手持3D打印制作的素片的剂量准确性,稳定性和溶解性.
主要方法:
- 使用异和水将素制成两个药用油墨棒 (30%和50%重/重素).
- 使用SSE技术的手持3D笔制造素片.
- 对剂量个性化,准确性,稳定性和溶解概况的评估.
主要成果:
- 精确制造素片 (200-700毫克),通过打印时间和区域选择实现剂量个性化.
- 优异的剂量准确性和恢复 (~100%),在12分钟内释放80%的素.
- 药用油墨棒在一个月内表现出稳定性,水损耗最小,保持可打印性和药物的完整性.
结论:
- 手持式3D笔是快速,个性化的药物制造的环保技术.
- 这项技术具有显著的潜力,可以在资源有限的环境中进行分散的,按需生产个性化疗法.
相关概念视频
In Vitro Drug Dissolution: Compendial Testing Models I
230
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
230
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
307
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
307
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151


